On September 1, one of the world's largest pharmaceutical companies made a quiet but revealing bet on China.
Roche agreed to pay $75 million upfront for global rights to SIM0660, an experimental blood-cancer treatment developed by China's Simcere Pharmaceutical Group. The molecule hasn't been tested in humans yet. Simcere's own filing calls it preclinical.
If it clears development, regulatory, and commercial milestones, the deal could pay out up to $1.53 billion total.
Think about what that means.
Roche isn't buying cheap manufacturing capacity. It's paying for an unproven asset before it has even entered the clinic.
And unlike some of the splashiest China deals this year, SIM0660 wasn't marketed as an AI-discovered drug. That distinction matters. The bigger story isn't that every Chinese molecule now comes from an algorithm.
It's that China's drug-development ecosystem can now produce intellectual property the world's biggest pharmaceutical companies want to buy, with or without AI attached.
Six days earlier, Jiangsu province, one of China's most important pharmaceutical hubs, said it would support drugmakers pursuing overseas licensing, joint development, and acquisitions.
Separately, IQVIA data show the scale of what's happening underneath: Chinese-headquartered sponsors ran 32% of all global clinical trials in 2025, up from just 2% in 2009.
Two data points. One story.
The AI Race Doesn't Stop At The Chip